Table of Content



Chapter 1 Methodology and Scope
1.1 Objectives
1.1.1. Objective - 1
1.1.2 Objective - 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage outlook
3.1.1 Parent Market Outlook
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Technological advancements
3.3.1.2 Initiatives by social organizations to improve the access of condom to avoid Sexually Transmitted Diseases (STDs)
3.3.1.3 Increasing Prevalance of unwanted pregnancies
3.3.2 Market Restraint Analysis
3.3.2.1 Increasing geriartic population and rising prevalence of infertility
3.3.2.2 Adverse effects associated with use of contraceptive drugs and devices
3.4 Business Environment Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
3.5 Penetration & Growth Prospect Mapping
3.5.1 Analysis
3.6 Pipeline Analysis
3.7 Regulatory Scenario and Reimbursement Framework, 2019
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Mergers Acquisition & Joint Ventures
3.8.2 Lisencing Partnerships & Technology Collaborations
Chapter 4 U.S. Contraceptive Market: Product Analysis
4.1 U.S. Contraceptive Product Market Share Analysis, 2019 & 2027
4.2 U.S. Contraceptive Product Market: Segment Dashboard
4.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Product Segment
4.3.1 PILLS
4.3.1.1 Pills market, 2016 - 2027 (USD Million)
4.3.2 Condoms
4.3.2.1 Condoms market, 2016 - 2027 (USD Million)
4.3.2.1.1 Male condom market, 2016 - 2027 (USD Million)
4.3.2.1.2 Female condom market, 2016 - 2027 (USD Million)
4.3.3 Diaphragms
4.3.3.1 Diaphragms Market, 2016 - 2027 (USD Million)
4.3.4 Sponge
4.3.4.1 Sponge market, 2016 - 2027 (USD Million)
4.3.5 Vaginal Ring
4.3.5.1 Vaginal ring market, 2016 - 2027 (USD Million)
4.3.6 Subdermal Implant
4.3.6.1 Subdermal implant market, 2016 - 2027 (USD Million)
4.3.7 IUD
4.3.7.1 IUD market, 2016 - 2027 (USD Million)
4.3.7.1.1 Hormonal IUD market, 2016 - 2027 (USD Million)
4.3.7.1.2 Nonhormonal IUD market, 2016 - 2027 (USD Million)
4.3.8 Patch
4.3.8.1 PATCH market, 2016 - 2027 (USD Million)
4.3.9 Injectable Contraceptives
4.3.9.1 Injectable market, 2016 - 2027 (USD Million)
Chapter 5 Competitive Analysis
5.1 Recent developments & impact analysis, by key market participants
5.2 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players)
5.3 Public & Private Companies
5.3.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Overall Revenue, And Strategic Initiatives)
5.4 Company Profiles
5.4.1 MERCK & CO., INC
5.4.1.1 Company overview
5.4.1.2 Financial performance
5.4.1.3 Product benchmarking
5.4.1.4 Strategic initiatives
5.4.1.5 SWOT analysis
5.4.2 BAYER AG
5.4.2.1 Company overview
5.4.2.2 Financial performance
5.4.2.3 Product benchmarking
5.4.2.4 Strategic initiatives
5.4.2.5 SWOT analysis
5.4.3 ALLERGAN
5.4.3.1 Company overview
5.4.3.2 Financial performance
5.4.3.3 Product benchmarking
5.4.3.4 Strategic initiative
5.4.3.5 SWOT analysis
5.4.4 PFIZER, INC.
5.4.4.1 Company overview
5.4.4.2 Financial Performance
5.4.4.3 Product benchmarking
5.4.4.4 Strategic initiatives
5.4.4.5 SWOT analysis
5.4.5 AFAXYS, INC.
5.4.5.1 Company overview
5.4.5.2 Product benchmarking
5.4.5.3 Strategic initiatives
5.4.5.4 SWOT analysis
5.4.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
5.4.6.1 Company overview
5.4.6.2 Financial performance
5.4.6.3 Strategic initiatives
5.4.6.4 SWOT analysis
5.4.7 AGILE THERAPEUTICS
5.4.7.1 Company overview
5.4.7.2 Financial performance
5.4.7.3 Product benchmarking
5.4.7.4 Strategic initiatives
5.4.7.5 SWOT analysis
5.4.8 APOTHECUS PHARMACEUTICAL CORP.
5.4.8.1 Company overview
5.4.8.2 Product benchmarking
5.4.9 MAYER LABORATORIES, INC.
5.4.9.1 Company overview
5.4.9.2 Product benchmarking
5.4.10 THE COOPER COMPANIES, INC.
5.4.10.1 Company overview
5.4.10.2 Financial performance
5.4.10.3 Product benchmarking
5.4.10.4 Strategic initiative
5.4.10.5 SWOT analysis
5.4.11 BLAIREX LABORATORIES, INC.
5.4.11.1 Company overview
5.4.11.2 Product benchmarking
5.4.12 THERAPEUTICSMD, INC.
5.4.12.1 Company overview
5.4.12.2 Financial performance
5.4.12.3 Product benchmarking
5.4.12.4 Strategic initiative
5.4.12.5 SWOT analysis
5.4.13 MITHRA PHARMACEUTICALS
5.4.13.1 Company overview
5.4.13.2 Financial performance
5.4.13.3 Product benchmarking
5.4.13.4 Strategic initiatives
5.4.13.5 SWOT analysis
5.4.14 Church & Dwight Co., Inc.
5.4.14.1 Company overview
5.4.14.2 Financial performance
5.4.14.3 Product benchmarking
5.4.14.4 Strategic initiatives
5.4.14.5 SWOT analysis
5.4.15 Reckitt Benckiser Plc
5.4.15.1 Company overview
5.4.15.2 Financial performance
5.4.15.3 Product benchmarking
5.4.15.4 Strategic initiatives
5.4.15.5 SWOT analysis
Chapter 6 Recommendations
Chapter 7 Research Methodology & Scope
7.1 Market Definition
7.1.1 Product
7.2 Research Methodology
7.3 Information Procurement
7.3.1 Purchased Database
7.3.2 Gvr’s Internal Database
7.3.3 Secondary Sources
7.3.4 Primary Research
7.4 Information or Data Analysis
7.4.1 Data Analysis Models
7.5 Market Formulation & Validation
7.6 Model Details
7.6.1 Commodity Flow Analysis
7.6.2 Variable Analysis
7.7 List of Secondary Sources
7.8 List of Primary Sources
7.9 List of Abbreviations
Chapter 8 Report FAQs
8.1 How do I trust your report quality/data accuracy?
8.2 My research requirement is very specific; can I customize this report?
8.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
8.4 How do you arrive at these market numbers?
8.5 Who are your clients?
8.6 How will I receive this report?
Chapter 9 Appendix
Chapter 10 Compass - Cloud Based Report Delivery Platform
Chapter 11 Related Reports



List of Tables



Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 U.S. Contraceptive Market, By Product, 2016 - 2027 (USD million)